SCHEMBL2010139

SCHEMBL2010139

ClC1CCN(Cc2ccccc2)CC1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.69
SIGMAR1 Q99720 3/20 0.68
CCR3 P51677 1/20 0.67
MEN1 O00255 1/20 0.63
TSHR P16473 1/20 0.63
KMT2A Q03164 1/20 0.63
DRD2 P14416 1/20 0.62
DRD4 P21917 1/20 0.62
DRD3 P35462 1/20 0.62
BCHE P06276 1/20 0.61
BACE1 P56817 1/20 0.61
ABL1 P00519 1/20 0.58
RIN1 Q13671 1/20 0.58
ALDH1A1 P00352 1/20 0.57
CXCR4 P61073 1/20 0.57
HTR2A P28223 1/20 0.57
MC4R P32245 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6972698 0.88 ACHE (0.59) ACHESIGMAR1CCR3MEN1TSHR
SCHEMBL6972688 0.88 ACHE (0.59) ACHESIGMAR1CCR3MEN1TSHR
SCHEMBL8315434 0.85 ACHE (0.71) ACHESIGMAR1CCR3DRD2DRD4
SCHEMBL27608094 0.85 MEN1 (0.69) ACHESIGMAR1CCR3MEN1TSHR
SCHEMBL1519223 0.85 MEN1 (0.69) ACHESIGMAR1MEN1TSHRKMT2A
SCHEMBL3290324 0.83 MEN1 (0.68) ACHESIGMAR1CCR3MEN1TSHR
Hydrochloric Acid SCHEMBL2551741 0.83 MEN1 (0.68) ACHESIGMAR1MEN1TSHRKMT2A
SCHEMBL4257757 0.83 ACHE (0.69) ACHESIGMAR1CCR3MEN1TSHR
SCHEMBL7363662 0.83 ACHE (0.69) ACHESIGMAR1CCR3DRD2DRD4
SCHEMBL592839 0.82 MEN1 (0.66) ACHESIGMAR1MEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111171063-B Process method for synthesizing N-substituted piperidine-4-boric acid 大连双硼医药化工有限公司 2022-06-14 CN disclosed
CN-111171063-A Process method for synthesizing N-substituted piperidine-4-boric acid 大连双硼医药化工有限公司 2020-05-19 CN disclosed
CN-107074788-A Substituted heterocyclic derivatives, preparation method and application thereof 厦门大学 2017-08-18 CN disclosed
US-7960394-B2 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-14 US disclosed
US-20080275069-A1 Quinazoline Derivative MSD K.K. (JP) 2008-11-06 US disclosed
EP-1757594-A1 QUINAZOLINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-02-28 EP disclosed
EP-0773222-B1 CARBAPENEM DERIVATIVE EISAI CO LTD (JP) 2001-10-04 EP disclosed
US-6143744-A Sulfamide-metalloprotease inhibitors SYNTEX (U.S.A.) INC. (US) 2000-11-07 US disclosed
US-6130220-A ENZYME INHIBITORS SYNTEX (USA) INC. (US) 2000-10-10 US disclosed
US-6037341-A HAVING POTENT ANTIMICROBIAL EFFECTS OVER GRAM-POSITIVE BACTERIA AND GRAM-NEGATIVE BACTERIA EISAI CO., LTD. (JP) 2000-03-14 US disclosed
EP-0619818-B1 IMIDAZOYLALKYL SUBSTITUTED WITH A SIX MEMBERED NITROGEN CONTAINING HETEROCYCLIC RING SCHERING CORP (US) 1996-07-10 EP disclosed
EP-0619818-A1 IMIDAZOYLALKYL SUBSTITUTED WITH A SIX MEMBERED NITROGEN CONTAINING HETEROCYCLIC RING. SCHERING CORP (US) 1994-10-19 EP disclosed
WO-1993012107-A1 IMIDAZOYLALKYL SUBSTITUTED WITH A SIX MEMBERED NITROGEN CONTAINING HETEROCYCLIC RING SCHERING CORPORATION (US) 1993-06-24 WO disclosed
EP-0144729-B1 11-Substituted 5H,11H-pyrrolo[2,1-c][1,4]benzoxazepines, a process for their preparation and their use in medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1989-11-08 EP disclosed
US-4865764-A 5-aryl-11-substituted-5H,11H-pyrrolo[2,1-][1,4]benzoxazepines as hypotensive agents HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1989-09-12 US disclosed
EP-0300356-A1 5-Aryl-11-substituted-5H, 11H-pyrrolo[2,1-c][1,4]benzoxazepines, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1989-01-25 EP disclosed
US-4794110-A ENANTIOMORPHS HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1988-12-27 US disclosed
US-4681879-A 11-substituted 5H,11H-pyrrolo[2,1-c][1,4]benzoxazepines as antipsychotic and analgesic agents HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1987-07-21 US disclosed
US-4608374-A 11-substituted 5H,11H-pyrrolo[2,1-c][1,4]benzoxazepines as antipsychotic and analgesic agents HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1986-08-26 US disclosed
EP-0144729-A1 11-Substituted 5H,11H-pyrrolo[2,1-c][1,4]benzoxazepines, a process for their preparation and their use in medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1985-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275069-A1 Quinazoline Derivative HRH3, HRH4, HRH2 ACHE 657/4885SIGMAR1 500/4885CCR3 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.